As new Gilead CEO enters, cancer chief exits

Little more than two years after joining Gilead Sciences Inc. to lead the company's cancer fight, Dr. Alessandro Riva is leaving for an East Coast spinoff of an Indian drug maker. The move comes just days after Daniel O'Day took over the Foster City-based company (NASDAQ: GILD) as chairman and CEO. It continues a wave of Gilead departures. Riva, who will continue as Gilead's executive vice president of oncology therapeutics and cell therapy through the end of the month, wi ll become CEO of a 400-person…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news